The main strength of the present study is that we conducted a large study to compare the neoadjuvant effectiveness of three targeted therapy strategies (trastuzumab plus pyrotinib, trastuzumab, or trastuzumab plus pertuzumab) based on the same chemotherapy regimen in patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.